CNS Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
CNS Pharmaceuticals, Inc. (CNSP) reported Increase (Decrease) in Accounts Payable of -$111.26 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2023-08-14
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2023-06-30 was $790.03K, a 67424.27% increase year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2023-03-31 was -$901.30K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2022-12-31 was $2.22M, a 326.69% increase year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2022-09-30 was $146.72K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2022 was $1.70M, a 64.28% increase from fiscal 2021.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2021 was $1.04M, a 47.31% increase from fiscal 2020.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2020 was $702.66K, a 547.20% increase from fiscal 2019.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2019 was $108.57K, a 26.87% increase from fiscal 2018.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2023-06-30 | $790.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$111.26K 10-Q · filed 2023-08-14 | $2.11M derived: sum of 3 quarters · filed 2023-08-14 | $2.25M derived: sum of 4 quarters · filed 2023-08-14 |
| 2023-03-31 | -$901.30K 10-Q · filed 2023-05-15 | $1.32M derived: sum of 2 quarters · filed 2023-05-15 | $1.46M derived: sum of 3 quarters · filed 2023-05-15 | $1.46M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $2.36M derived: sum of 2 quarters · filed 2023-03-31 | $2.37M derived: sum of 3 quarters · filed 2023-08-14 | $1.70M 10-K · filed 2023-03-31 |
| 2022-09-30 | $146.72K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $147.89K derived: sum of 2 quarters · filed 2023-08-14 | -$517.78K 10-Q · filed 2022-11-10 | $2.09K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-06-30 | $1.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$664.50K 10-Q · filed 2023-08-14 | -$144.63K derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$665.67K 10-Q · filed 2023-05-15 | -$145.80K derived: sum of 2 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $519.87K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.04M 10-K · filed 2023-03-31 | ||
| 2021-09-30 | $515.24K 10-Q · filed 2022-11-10 | |||
| 2020-12-31 | $696.15K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $795.82K derived: sum of 2 quarters · filed 2021-02-12 | $805.08K derived: sum of 3 quarters · filed 2021-02-12 | $702.66K 10-K · filed 2021-02-12 |
| 2020-09-30 | $99.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $108.93K derived: sum of 2 quarters · filed 2020-11-12 | $6.51K 10-Q · filed 2020-11-12 | -$35.19K derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-06-30 | $9.27K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$93.15K 10-Q · filed 2020-08-10 | -$134.85K derived: sum of 3 quarters · filed 2021-02-12 | -$21.47K derived: sum of 4 quarters · filed 2021-02-12 |
| 2020-03-31 | -$102.42K 10-Q · filed 2020-05-15 | -$144.12K derived: sum of 2 quarters · filed 2021-02-12 | -$30.74K derived: sum of 3 quarters · filed 2021-02-12 | -$52.81K derived: sum of 4 quarters · filed 2021-02-12 |
| 2019-12-31 | -$41.70K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $71.68K derived: sum of 2 quarters · filed 2021-02-12 | $49.60K derived: sum of 3 quarters · filed 2021-02-12 | $108.57K 10-K · filed 2021-02-12 |
| 2019-09-30 | $113.38K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $91.31K derived: sum of 2 quarters · filed 2020-11-12 | $150.27K 10-Q · filed 2020-11-12 | $187.55K derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$22.07K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $36.89K 10-Q · filed 2020-08-10 | $74.17K derived: sum of 3 quarters · filed 2020-08-10 | |
| 2019-03-31 | $58.97K 10-Q · filed 2020-05-15 | $96.24K derived: sum of 2 quarters · filed 2020-05-15 | ||
| 2018-12-31 | $37.28K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $85.57K 10-K · filed 2020-03-12 | ||
| 2018-09-30 | $48.30K 10-Q · filed 2019-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |